{"id":2300,"date":"2024-03-28T10:43:46","date_gmt":"2024-03-28T09:43:46","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2300"},"modified":"2025-11-25T10:44:05","modified_gmt":"2025-11-25T09:44:05","slug":"a-covid-19-oltasok-eredmenyessege-a-sars-cov-2-ba-1-es-ba-2-alagak-altal-okozott-tunetes-megbetegedesekkel-szemben-a-felnottek-es-serdulok-koreben","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2024\/03\/28\/a-covid-19-oltasok-eredmenyessege-a-sars-cov-2-ba-1-es-ba-2-alagak-altal-okozott-tunetes-megbetegedesekkel-szemben-a-felnottek-es-serdulok-koreben\/","title":{"rendered":"A Covid-19 olt\u00e1sok eredm\u00e9nyess\u00e9ge a SARS-CoV-2 BA.1 \u00e9s BA.2 al\u00e1gak \u00e1ltal okozott t\u00fcnetes megbeteged\u00e9sekkel szemben a feln\u0151ttek \u00e9s serd\u00fcl\u0151k k\u00f6r\u00e9ben"},"content":{"rendered":"

\u00a0A VEBIS* eur\u00f3pai vizsg\u00e1lat\u00e1nak eredm\u00e9nyei 2021. december \u2013 2022. j\u00fanius k\u00f6z\u00f6tt<\/strong><\/h3>\n

A 2021\/22-es l\u00e9g\u00fati szezonban Eur\u00f3p\u00e1ban az Omikron BA.1 \u00e9s BA.2 alvari\u00e1nsai ellen alacsonyabb v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get m\u00e9rtek, a kialakult v\u00e9delem pedig gyorsan cs\u00f6kkent. Err\u0151l az id\u0151szakr\u00f3l ugyanakkor az adatok csak korl\u00e1tozottan \u00e1lltak rendelkez\u00e9sre, \u00edgy a v\u00e9detts\u00e9g szintj\u00e9re \u00e9s annak id\u0151beli v\u00e1ltoz\u00e1s\u00e1ra vonatkoz\u00f3 eredm\u00e9nyek csak r\u00e9szlegesen ismertek.<\/p>\n

Vizsg\u00e1latunk c\u00e9lja az volt, hogy meghat\u00e1rozzuk, a teljes els\u0151dleges olt\u00e1si sor \u00e9s az els\u0151 eml\u00e9keztet\u0151 olt\u00e1s milyen m\u00e9rt\u00e9k\u0171 v\u00e9delmet biztos\u00edtott a t\u00fcnetes BA.1- vagy BA.2-fert\u0151z\u00e9ssel szemben, tov\u00e1bb\u00e1 felt\u00e1rjuk azokat a t\u00e9nyez\u0151ket, amelyek torz\u00edthatj\u00e1k a v\u00e9d\u0151olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9re vonatkoz\u00f3 becsl\u00e9seket.<\/p>\n

Az Eur\u00f3p\u00e1ban v\u00e9gzett, t\u00f6bbk\u00f6zpont\u00fa, teszt-negat\u00edv kutat\u00e1sunkban a BA.1 \u00e9s BA.2 dominanci\u00e1j\u00e1nak id\u0151szak\u00e1ban akut l\u00e9g\u00fati megbeteged\u00e9s (ARI) t\u00fcneteivel h\u00e1ziorvoshoz fordul\u00f3 p\u00e1ciensek adatait elemezt\u00fck. Minden ARI p\u00e1cienst RT-PCR m\u00f3dszerrel tesztelt\u00fcnk, \u00e9s a SARS-CoV-2-pozit\u00edvokat esetk\u00e9nt, a negat\u00edvokat kontrollk\u00e9nt defini\u00e1ltuk. A vizsg\u00e1lat keret\u00e9ben megbecs\u00fclt\u00fck a teljes, els\u0151dleges olt\u00e1si sorozat \u00e9s az eml\u00e9keztet\u0151 olt\u00e1sok eredm\u00e9nyess\u00e9g\u00e9t a feln\u0151ttek \u00e9s a serd\u00fcl\u0151kor\u00fa n\u00e9pess\u00e9g k\u00f6r\u00e9ben, mind az \u00f6sszes olt\u00f3anyagra, mind k\u00fcl\u00f6n a Comirnaty olt\u00f3anyagra vonatkoz\u00f3an.<\/p>\n

Az elemz\u00e9s sor\u00e1n kit\u00e9rt\u00fcnk arra is, hogy van-e \u00f6sszef\u00fcgg\u00e9s a p\u00e1ciensek influenza- \u00e9s Covid\u201119 oltotts\u00e1gi st\u00e1tusza k\u00f6z\u00f6tt, \u00e9s hogy ez, vagy a kor\u00e1bbi SARS\u2011CoV\u20112-fert\u0151z\u00e9s befoly\u00e1solhatja vagy torz\u00edthatja-e az eredm\u00e9nyeket. Emellett azt is vizsg\u00e1ltuk, hogy bizonyos t\u00e9nyez\u0151k \u2013 p\u00e9ld\u00e1ul az olt\u00e1s \u00f3ta eltelt id\u0151, az \u00e9letkor vagy a kr\u00f3nikus betegs\u00e9gek \u2013 m\u00f3dos\u00edthatj\u00e1k-e az olt\u00e1sok hat\u00e1s\u00e1t.<\/p>\n

Feln\u0151ttek k\u00f6r\u00e9ben az els\u0151dleges olt\u00e1si sorozat v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9ge (VE) \u00e1tlagosan 37% volt, m\u00edg az eml\u00e9keztet\u0151 olt\u00e1sok VE-e 42%. Az olt\u00e1s \u00f3ta eltelt id\u0151 f\u00fcggv\u00e9ny\u00e9ben a VE eredm\u00e9nyek az 1. \u00e1bra<\/em> \u00e9rt\u00e9kei szerint alakultak.<\/p>\n

Ha kiz\u00e1r\u00f3lag a Comirnaty olt\u00f3anyag eredm\u00e9nyeit vessz\u00fck figyelembe, a VE becsl\u00e9sek k\u00f6zel megegyeznek az \u00f6sszes olt\u00f3anyagra vonatkoz\u00f3 \u00e9rt\u00e9kekkel. Az eredm\u00e9nyeink szerint az 50 \u00e9v feletti feln\u0151tt n\u00e9pess\u00e9g k\u00f6r\u00e9ben magasabb volt a v\u00e9detts\u00e9g szintje, mint a fiatalabb feln\u0151ttekn\u00e9l.<\/p>\n

Az elv\u00e9gzett elemz\u00e9sek alapj\u00e1n az influenza- \u00e9s Covid\u201119-olt\u00e1si st\u00e1tusz \u00f6sszef\u00fcgg\u00e9sei nem torz\u00edtott\u00e1k a becsl\u00e9seket \u00e9s a kor\u00e1bbi SARS\u2011CoV\u20112-fert\u0151z\u00e9s hat\u00e1sa is alacsonynak bizonyult. Ugyanakkor a hat\u00e1sm\u00f3dos\u00edt\u00f3 t\u00e9nyez\u0151k pontos felm\u00e9r\u00e9s\u00e9re az alacsony esetsz\u00e1mok miatt nem volt lehet\u0151s\u00e9g.<\/p>\n

A teljes, els\u0151dleges olt\u00e1si sorozat, valamint az eml\u00e9keztet\u0151 olt\u00e1s eredm\u00e9nyess\u00e9ge a BA.1 \u00e9s BA.2 alvonalakkal szemben m\u00e9rs\u00e9keltnek bizonyult a t\u00fcnetes megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben, \u00e9s az olt\u00e1st k\u00f6vet\u0151en mindk\u00e9t alvari\u00e1ns eset\u00e9ben hasonl\u00f3 m\u00e9rt\u00e9kben cs\u00f6kkent az immunit\u00e1s. A v\u00e9d\u0151olt\u00e1sok \u00e9s a fert\u0151z\u00e9s \u00e1ltal kialakult v\u00e9detts\u00e9g hat\u00e1s\u00e1nak egy\u00e9rtelm\u0171bb elk\u00fcl\u00f6n\u00edt\u00e9s\u00e9t seg\u00edten\u00e9 a kor\u00e1bbi SARS-CoV-2-fert\u0151z\u00e9sekr\u0151l sz\u00f3l\u00f3 r\u00e9szletesebb adatok megismer\u00e9se \u00e9s ki\u00e9rt\u00e9kel\u00e9se.<\/p>\n

    \n
  1. \u00e1bra: Covid-19 elleni v\u00e9d\u0151olt\u00e1s eredm\u00e9nyess\u00e9g a feln\u0151ttek k\u00f6r\u00e9ben az olt\u00e1s \u00f3ta eltelt id\u0151 szerint, az \u00f6sszes olt\u00f3anyagra \u00e9s kiz\u00e1r\u00f3lag a Comirnaty olt\u00f3anyagra, VEBIS, h\u00e1ziorvosi vizsg\u00e1lat, EU\/EEA, 2021. december \u2013 2022. j\u00fanius<\/strong><\/span><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    EEA: Eur\u00f3pai Gazdas\u00e1gi T\u00e9rs\u00e9g; EU: Eur\u00f3pai Uni\u00f3; VE: v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g; VEBIS: Vaccine Effectiveness, Burden and Impact Studies.<\/span>
    \nAz \u00e1bra alj\u00e1n f\u00fcgg\u0151legesen l\u00e1that\u00f3 n\u00e9gy sz\u00e1m: az esetek sz\u00e1ma \/ oltott esetek sz\u00e1ma; a kontrollok sz\u00e1ma \/ oltott kontrollok sz\u00e1ma a teljes n\u00e9pess\u00e9gre \u00e9s az id\u0151intervallumokra vonatkoz\u00f3an. A vonalak a 95%-os konfidencia intervallumot jel\u00f6lik.<\/span>
    \nForr\u00e1s: Euro Surveill. 2024 Mar 28;29(13):2300403. doi: 10.2807\/1560-7917.ES.2024.29.13.2300403 publik\u00e1ci\u00f3 4. t\u00e1bl\u00e1zata alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span>
    \n(Az \u00e1bra nem teljes, kiz\u00e1r\u00f3lag a feln\u0151ttek eredm\u00e9nyeit mutatja be.)<\/span><\/p>\n

     <\/p>\n

    COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1\/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022<\/strong><\/h5>\n

    Charlotte Lani\u00e8ce Delaunay <\/em>(Epiconcept, Paris, France)
    \nIv\u00e1n Mart\u00ednez-Baz \u00a0<\/em>(N Instituto de Salud P\u00fablica de Navarra – IdiSNA, Pamplona, Spain)
    \nJudit Krisztina Horv\u00e1th <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nand the VEBIS primary care study group<\/em><\/p>\n

    Abstract<\/strong><\/h5>\n

    Background
    \n<\/em>Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.<\/p>\n

    Aim
    \n<\/em>We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1\/BA.2 infection and investigate potential biases.<\/p>\n

    Methods
    \n<\/em>This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1\/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.<\/p>\n

    Results
    \n<\/em>Among adults, PS VE was 37% (95%\u202fCI: 24\u201347%) overall and 60% (95%\u202fCI: 44\u201372%), 43% (95%\u202fCI: 26\u201355%) and 29% (95%\u202fCI: 13\u201343%)\u2009<\u200990, 90\u2013179 and\u2009\u2265\u2009180 days post vaccination, respectively. Booster VE was 42% (95%\u202fCI: 32\u201351%) overall and 56% (95%\u202fCI: 47\u201364%), 22% (95%\u202fCI: 2\u201338%) and 3% (95%\u202fCI: \u221278% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.<\/p>\n

    Conclusion
    \n<\/em>Primary series and booster VE against symptomatic infection with BA.1\/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.<\/p>\n

    * Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

    Lani\u00e8ce Delaunay C, Mart\u00ednez-Baz I, S\u00e8ve N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ili\u0107 M, Maurel M, Melo A, Sandonis Mart\u00edn V, Trobajo-Sanmart\u00edn C, Enouf V, McKenna A, P\u00e9rez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, T\u00fari G, Castilla J, Falchi A, Bennett C, Gallardo V, D\u00fcrrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horv\u00e1th JK, Casado I, Garc\u00eda MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; European Primary Care Vaccine Effectiveness Group. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1\/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. Euro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807\/1560-7917.ES.2024.29.13.2300403. PMID: 38551095; PMCID: PMC10979526.<\/p>\n

    https:\/\/pubmed.ncbi.nlm.nih.gov\/38551095\/\u00a0<\/strong><\/p>\n

    K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

    \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

    \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    \u00a0A VEBIS* eur\u00f3pai vizsg\u00e1lat\u00e1nak eredm\u00e9nyei 2021. december \u2013 2022. j\u00fanius k\u00f6z\u00f6tt A 2021\/22-es l\u00e9g\u00fati szezonban Eur\u00f3p\u00e1ban az Omikron BA.1 \u00e9s BA.2 alvari\u00e1nsai ellen alacsonyabb v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9get m\u00e9rtek, a kialakult v\u00e9delem pedig gyorsan cs\u00f6kkent. Err\u0151l az id\u0151szakr\u00f3l ugyanakkor az adatok csak korl\u00e1tozottan \u00e1lltak rendelkez\u00e9sre, \u00edgy a v\u00e9detts\u00e9g szintj\u00e9re \u00e9s annak id\u0151beli v\u00e1ltoz\u00e1s\u00e1ra vonatkoz\u00f3 eredm\u00e9nyek csak r\u00e9szlegesen ismertek. …<\/p>\n","protected":false},"author":102284,"featured_media":2301,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2300"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2300\/revisions"}],"predecessor-version":[{"id":2302,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2300\/revisions\/2302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2301"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}